In addition, subjects treated with exenatide also demonstrated reductions in markers of cardiac damage, which include circulating levels of creatine kinase-MB and troponin I. While these studies provide more support for GLP-1R agonists being cardioprotective in the setting of ischemic heart disease, the study populations are not equivalent to those enrolled in CVOTs of subjects with T2DM. The gene discussed is GLP1R; the disease is coronary artery disorder.